Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
Neumora Therapeutics President Joshua Pinto reported a Form 4 showing the sale of 5,967 shares of common stock at $3.535 per share on February 17, 2026. According to the footnote, the shares were sold solely to satisfy tax withholding obligations tied to vesting restricted stock units. After this tax-related sale, Pinto directly holds 57,783 shares, and an additional 152,167 shares are held indirectly by Maple DE Holdings LLC.
Neumora Therapeutics, Inc. director and officer Paul L. Berns reported an open-market sale of 9,819 shares of common stock on February 17, 2026. The shares were sold at a weighted average price of $3.5094 per share to satisfy tax withholding obligations related to the vesting of restricted stock units.
After the sale, Berns directly owned 7,395,185 shares of common stock. He also had indirect ownership of 133,097 shares held by LULU TRUST OF 2024 for specified beneficiaries, as noted in the footnotes.
Neumora Therapeutics officer Michael Lee Milligan reported an open-market sale of 1,436 shares of common stock at $3.565 per share. The February 17 transaction was executed under a pre-established Rule 10b5-1 trading plan that automatically sells shares on each covered restricted stock unit vesting date to satisfy withholding obligations.
After this sale, Milligan directly held 21,034 Neumora common shares. The filing describes an automated, plan-driven disposition rather than a discretionary trade decision.
Neumora Therapeutics ownership disclosure: Reporting persons led by Invus Public Equities, L.P. state beneficial ownership as of February 13, 2026. Invus Public Equities directly held 8,172,814 shares and Avicenna Life Sci Master Fund directly held 825,008 shares.
The filing shows Raymond Debbane may be deemed beneficial owner of 8,997,822 shares, representing 5.4% based on 167,089,114 shares outstanding as of November 1, 2025, per the issuer's Form 10-Q. The reporting persons certify the holdings were not acquired to change or influence control.
K2 HealthVentures Equity Trust LLC and its managing members Parag Shah and Anup Arora report a 5.01% beneficial ownership stake in Neumora Therapeutics, Inc. common stock as of December 31, 2025. They may be deemed to beneficially own 8,997,035 shares in total.
This consists of 1,055,899 shares held directly by K2 HealthVentures Equity Trust and 7,941,136 additional shares that the trust has the right to acquire within 60 days through conversion of the issuer’s outstanding debt. These conversion rights arise under a Loan and Security Agreement originally dated May 9, 2025 and later amended.
All 8,997,035 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power. The filers certify the securities were not acquired and are not held for the purpose of changing or influencing control of Neumora Therapeutics.
Neumora Therapeutics, Inc. reported a planned Rule 144 sale of common stock by an affiliated holder. The notice covers 5,967 shares of common stock, with an aggregate market value of $21,093.35, to be sold through Merrill Lynch on NASDAQ around 02/17/2026.
The shares were acquired on 02/14/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan. Neumora reports that 167,089,114 shares of common stock were outstanding, providing context for the size of this prospective sale.
Neumora Therapeutics, Inc. has a planned sale notice under Rule 144 covering 9,819 shares of common stock. The shares are to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $34,458.98 and an approximate sale date of February 17, 2026.
The securities were acquired on February 14, 2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan.
Neumora Therapeutics (NMRA) had a security holder file a notice of proposed sale of 6,165 shares of common stock under Rule 144. The planned sale, through Merrill Lynch on NASDAQ around 02/17/2026, had an aggregate market value of $21,916.58 at the time of the notice.
The shares come from a restricted stock unit award that vested on 02/14/2026 and was granted as part of the issuer’s equity compensation plan. Neumora had 167,089,114 shares of common stock outstanding, which is a baseline figure for the company’s total equity.
Neumora Therapeutics, Inc. is the issuer for a planned sale of restricted shares under Rule 144. The notice covers the proposed sale of 1,436 shares of common stock through Merrill Lynch on or around 02/17/2026 on the NASDAQ market, with an aggregate market value of $5,119.34. These shares were acquired on 02/14/2026 through the vesting of a restricted stock unit award granted under the company’s equity compensation plan. The filing notes that 167,089,114 shares of common stock were outstanding at the time referenced.
Neumora Therapeutics furnished a corporate presentation for use at the Guggenheim Emerging Outlook: Biotech Summit, highlighting Phase 1b data for NMRA-511 in agitation associated with Alzheimer’s disease. The randomized, double-blind study enrolled 40 patients on NMRA-511 and 40 on placebo over eight weeks, plus a small healthy-elderly cohort.
In a pre-specified elevated anxiety subgroup, NMRA-511 showed Cohen’s d effect sizes of 0.51–0.64 on the CMAI agitation scale, up to 0.78 on CGI-S agitation, and 0.42–0.46 on the NPI agitation/aggression domain, with nominal p-values down to <0.05. Treatment-emergent adverse events were generally mild to moderate, discontinuations due to side effects were 2.5%, and one serious adverse event resolved fully. The company notes potential for higher dosing and future studies that enrich for patients with elevated anxiety.